BioCentury
ARTICLE | Clinical News

Valeant receives complete response letter for psoriasis candidate

June 22, 2018 5:56 PM UTC

The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from FDA to an NDA for Duobrii (IDP-118) to treat plaque psoriasis.

According to Valeant, FDA had questions related to pharmacokinetic data...

BCIQ Company Profiles

Bausch Health Companies Inc.